Nhl_follicular. What does it mean and what should I know

NHL - FollicularMarch 30, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Understanding Follicular Lymphoma (NHL - Follicular)

I appreciate you asking this important question. However, I notice something that needs clarification: Your Travera report appears to be about pancreatic cancer (specifically pancreatic adenocarcinoma with a lung metastasis), not follicular lymphoma.

Let me help you understand both what your report shows AND what follicular lymphoma is, so you have complete information.


What Your Travera Report Actually Shows

Your January 21st biopsy report tested cancer cells from a lung specimen (which was a metastasis—a spread from pancreatic cancer). The test measured how your tumor cells respond to two chemotherapy drugs:

  • FOLFIRI - Score of 100 (highly sensitive)
  • Oxaliplatin - Score of 100 (highly sensitive)

Both drugs showed strong responses in your tumor cells, which is encouraging information for treatment planning.


About Follicular Lymphoma (If This Applies to You)

If you've been diagnosed with follicular lymphoma (FL), here's what you should know:

What It Is

According to the NCCN Guidelines for Patients: Follicular Lymphoma, follicular lymphoma is:

  • A type of non-Hodgkin lymphoma (NHL) that develops from B-cell lymphocytes (a type of white blood cell)
  • A slow-growing cancer (unlike the fast-growing pancreatic cancer shown in your Travera report)
  • Commonly found in lymph nodes, but can also affect the spleen, liver, bone marrow, or other tissues

Key Characteristics

Symptoms may include:

  • Swollen lymph nodes (usually painless) in the neck, armpit, or groin
  • Fever, night sweats, fatigue, and weight loss (called "B symptoms")
  • Not everyone has symptoms—some people are diagnosed incidentally

Cell markers (from NCCN Guidelines):

  • FL typically shows specific protein patterns: CD10+, BCL2+, CD20+, BCL6+
  • Most follicular lymphomas test positive for a genetic change called t(14;18) or have BCL2 mutations

Important Questions for Your Care Team

Given the discrepancy between your Travera report (pancreatic cancer) and your question about follicular lymphoma, I'd recommend asking:

  1. "Do I have follicular lymphoma, pancreatic cancer, or both? Can you clarify my diagnosis?"
  2. "What does the Travera test result mean for my specific treatment plan?"
  3. "Are there other biopsy results or pathology reports I should review to understand my complete diagnosis?"
  4. "Which specialist should I be seeing—an oncologist for pancreatic cancer, a hematologist for lymphoma, or both?"
  5. "Can you explain how my different test results connect to create my overall treatment strategy?"

Why This Matters

Understanding your actual diagnosis is crucial because:

  • Pancreatic cancer and follicular lymphoma are treated very differently
  • Your Travera report provides drug sensitivity information specific to pancreatic cancer
  • If you have both conditions, your treatment plan would need to address each appropriately

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.


Would you like me to help you understand your Travera report in more detail, or do you have other medical documents that clarify your diagnosis?

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: